Organon & co OGN.US Overview Analysis
OGN AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
OGN Current Performance
-1.20%
Organon & co
-0.65%
Avg of Sector
0.16%
S&P500
Top 10 High Relevance to OGN
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
SGMT | Sagimet biosciences inc | - | 4 | 3 | 1 | 1 | |
NVS | Novartis ag | 3 | 1 | 4 | 3 | 5 | |
KYTX | Kyverna therapeutics inc | - | 1 | 2 | 2 | 1 | |
CPHI | China pharma holdings, inc. | 2 | 3 | 3 | - | 1 | |
AZN | Astrazeneca plc | 3 | 2 | 4 | 3 | 5 |
- SGMT Sagimet biosciences incValue -Trend 4Swing Trading 3Whale Interest 1Dividend 1See more
OGN Profile
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.